Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | HTRA1 | Q92743 | 2/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31679039 | 0.92 | KLK7 (0.49) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL30341831 | 0.92 | KLK7 (0.49) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL31679036 | 0.91 | KLK7 (0.54) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL31679025 | 0.89 | KLK7 (0.50) | KLK7KLK5MAPTITGB3ITGA2B | |
| SCHEMBL22117406 | 0.87 | SIRT2 (0.50) | SIRT2CTSL | |
| SCHEMBL22117407 | 0.87 | SIRT2 (0.50) | SIRT2CTSL | |
| SCHEMBL26212052 | 0.86 | DPP8 (0.49) | SIRT2HTRA1CTSL | |
| SCHEMBL22117420 | 0.86 | HDAC1 (0.48) | ITGB3ITGA2B | |
| SCHEMBL22117419 | 0.86 | HDAC1 (0.48) | ITGB3ITGA2B | |
| SCHEMBL2801426 | 0.86 | MAPT (0.66) | KLK7KLK5MAPTITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404300-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4168423-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | ARG2, NLN, OAT | KLK7 4302/4885KLK5 4778/4885MAPT 1576/4885 |
| US-12404300-B2 | Mitochondria-targeting peptides | SSBP1, HSPE1, IMMT | KLK7 4426/4885KLK5 4428/4885MAPT 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.